CN106389404A - Applications of Linderolide H in preparing medicines for treating rhinitis - Google Patents
Applications of Linderolide H in preparing medicines for treating rhinitis Download PDFInfo
- Publication number
- CN106389404A CN106389404A CN201610803401.XA CN201610803401A CN106389404A CN 106389404 A CN106389404 A CN 106389404A CN 201610803401 A CN201610803401 A CN 201610803401A CN 106389404 A CN106389404 A CN 106389404A
- Authority
- CN
- China
- Prior art keywords
- linderolide
- rhinitis
- applications
- treating rhinitis
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to Linderolide H for treating immune inflammation, used for preparing medicines for treating immune inflammation, especially the medicines for treating rhinitis. According to the applications, terfenadine and diclofenac sodium are taken as contrasts, the curative effects of Linderolide H are definite, the applications of Linderolide H in preparing medicines for treating rhinitis are disclosed for the first time, the skeleton type belongs to the brand-new skeleton type, and Linderolide H has strong activity in treating rhinitis, has the outstanding substantive features, and obviously has the remarkable progress in preventing and treating rhinitis.
Description
Technical field
The present invention relates to the new application of compound L inderolide H, more particularly, to Linderolide H are in preparation treatment
Application in rhinitis medicine.
Background technology
Rhinitis is common clinical and frequently-occurring disease, and the generation of rhinitis is mainly relevant with anaphylaxiss, belongs to immune inflammation
Category.At present, treatment rhinitis mainly adopts the antiallergic agents such as antihistamine drug or tranilast, ketotifen such as teldane
Thing, these medicines are poor or invalid to the chronicity of rhinitis and recurrent exerbation curative effect.Therefore, definite ingredients, quality controllable and peace
Efficient micromolecular compound, in terms of developing treatment of rhinitis medicine, has potential value entirely.
Compound L inderolide H according to the present invention be one deliver within 2012 (Qing Liu, et al.,
Sesquiterpene lactones from the roots of Lindera
Strychnifolia.Phytochemistry, 87 (2013) 112 118.) noval chemical compound, this compound has brand-new bone
Frame type, is only capable of suppressing tumor cell proliferation (Qing Liu, et al., Sesquiterpene lactones from the
Roots of Lindera strychnifol ia.Phytochemistry, 87 (2013) 112 118.), according to the present invention
Purposes in preparation treatment rhinitis medicine for the Linderol ide H belongs to first public.
Content of the invention
It is an object of the invention to not finding in studying according to existing Linderolide H that it has the report of anti-rhinitis activity
The present situation in road, there is provided application in preparing anti-rhinitis medicament thing for the Linderolide H.
Described compound L inderolide H, structure is as shown in formula I：
Linderolide H 10,20mg/kg oral administration, nose that rat caused by antigen (ovalbumin) and histamine is scratched
Portion, sneeze reaction and the rising of nasal cavity vascular permeability are inhibited, therefore, can be used for preparing the medicine for the treatment of rhinitis.
Purposes in preparation treatment rhinitis medicine for the Linderolide H belongs to first public, because framework types belong to
Brand-new framework types, and its treatment rhinitis activity is strong, possesses prominent substantive distinguishing features, the preventing and treating being simultaneously used for rhinitis shows
So have and significantly improve.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to concrete reality
Apply any restriction of example, but be defined in the claims.
Specific embodiment
The preparation method of compound L inderolide H involved in the present invention referring to document (Qing Liu, et al.,
Sesquiterpene lactones from the roots of Lindera
strychnifolia.Phytochemistry,87(2013)112–118.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to concrete reality
Apply any restriction of example, but be defined in the claims.
Embodiment 1：The preparation of compound L inderol ide H tablet involved in the present invention：
Take 5 g of compound Linderolide H, add 195 grams of dextrin, mix, Conventional compression makes 1000.
Embodiment 2：The preparation of compound L inderol ide H capsule involved in the present invention：
Take 5 g of compound Linderolide H, add 180 grams of starch, mix, encapsulated make 1000.
To further illustrate its pharmaceutically active below by pharmacodynamic experiment.
Experimental example 1, Linderolide H of the present invention cause the impact of rat allergic rhinitises to ovalbumin
Male SD rat, body weight 180～220g, lumbar injection ovalbumin 1mg and gel aluminum hydroxide 10mg, thereafter every
Day injection 1 time, totally 7 times.Began from the 14th day, instill 1mg/ml ovalbumin normal saline solution in rat both sides nasal cavity daily
10ul, totally 7 times.Last observes rat sneeze and the number of times wiping nose in 30 minutes at once after instiling, trial drug is in white of an egg egg
White last instils and is orally administered to for first 1 hour.
Table 1 Linderolide H of the present invention causes the impact (x ± SD) of rat allergic rhinitises to ovalbumin
Compare with matched group, * * P<0.01*P<0.05
From table 1, Linderolide H (10,20mg/kg) substantially suppresses allergic rhinitises rat caused by ovalbumin
Sneeze and scratch nose reaction.Teldane 10mg/kg also assumes significant inhibitory action.
The impact of the rat rhinitis that experimental example 2, Linderolide H of the present invention cause to histamine
Male SD rat, body weight 180～220g, it is orally administered to 1 hour after trial drug, both sides nasal cavity instills 1M histamine
Normal saline solution 10ul, observes rat sneeze and the number of times wiping nose in 30 minutes.
Table 2 Linderolide H of the present invention causes the impact (x ± SD) of rat rhinitis to histamine
Compare with matched group, * * P<0.01*P<0.05
From table 2, Linderolide H (10,20mg/kg) of the present invention significantly reduces the spray of rhinitis rat caused by histamine
Sneeze number of times, the nose reaction to scratching is in suppression trend.Teldane 10mg/kg is in then significant inhibitory action.
Conclusion：Linderolide H oral administration, nose that rat caused by antigen (ovalbumin) and histamine is scratched, beats
Sneeze reaction is inhibited, therefore, can be used for preparing the medicine for the treatment of rhinitis.
Claims (1)
- Application in treatment rhinitis medicine for the 1.Linderolide H, described compound L inderolide H structure such as formula I Shown：
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610803401.XA CN106389404A (en) | 2016-09-05 | 2016-09-05 | Applications of Linderolide H in preparing medicines for treating rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610803401.XA CN106389404A (en) | 2016-09-05 | 2016-09-05 | Applications of Linderolide H in preparing medicines for treating rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106389404A true CN106389404A (en) | 2017-02-15 |
Family
ID=57999829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610803401.XA Pending CN106389404A (en) | 2016-09-05 | 2016-09-05 | Applications of Linderolide H in preparing medicines for treating rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106389404A (en) |
-
2016
- 2016-09-05 CN CN201610803401.XA patent/CN106389404A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015143475A (en) | PRODUCT AND METHOD FOR TREATING DIARRHEA | |
| CN106389404A (en) | Applications of Linderolide H in preparing medicines for treating rhinitis | |
| CN103585150B (en) | Use of Nitrosporeusines A in drugs for treating rhinitis | |
| JP2019535830A5 (en) | ||
| CN105362274A (en) | Application of biscarpamontamine A in preparation of rhinitis pharmaceuticals | |
| EP2727595B1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| CN102872034B (en) | Application of Gypensapogenin B in medicaments for treating rhinitis | |
| CN103494826B (en) | The application of Phyllanthoid A in preparation treatment rhinitis medicine | |
| KR20180074707A (en) | Low dose oral dipyridamole compositions and uses thereof | |
| CN103463007A (en) | Application of racemosins A in preparation of medicine treating rhinitis | |
| CN105287545A (en) | Applications of Strynuxlines A in preparation of rhinitis treatment drugs | |
| CN106551936A (en) | One kind treats rhinitis medicine and its application | |
| CN106491617A (en) | Applications of the Friedolanostanes in treatment rhinitis medicine is prepared | |
| CN103751170B (en) | The application of Trigoxyphin K in treatment rhinitis medicine | |
| CN103330712A (en) | Application of Myriberine A in preparation of a medicine for treating rhinitis | |
| CN107865846A (en) | Isovitexin is preparing the application in treating rhinitis medicine | |
| CN107865862A (en) | Apigenin is preparing the application in treating rhinitis medicine | |
| CN105456246A (en) | Application of Lathyranone A in preparation of drug for treating rhinitis | |
| CN105125533A (en) | Medicine for treating rhinitis and application thereof | |
| CN103393699B (en) | The application of Chukrasone A in preparation treatment rhinitis medicine | |
| CN103372006B (en) | The application of Chukrasone B in preparation treatment rhinitis medicine | |
| CN103462999A (en) | Application of Neonectrolide A in preparing medicament for treating rhinitis | |
| CN105287495A (en) | Application of Sphenostylisins C in preparation of drugs used for treating rhinitis | |
| JP2009263384A (en) | Internal medicine for inhibiting symptom of atopic dermatitis of type i allergic disorder | |
| CN103638007A (en) | Application of Hippolachnin A in medicine for treatment of rhinitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170215 |